A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Clinical trial NCT03392246 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03392246
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-31
- Primary completion
- 2027-06-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.